Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy
Recent studies reported that cytoplasmic dsDNA-induced activation of cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling has tremendous potential for antitumor immunity by inducing the production of type I Interferon (IFN), resulting in activation of both innate and adapt...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2025.1556736/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850272228108664832 |
|---|---|
| author | Hao Chen Yang Zhong Yang Zhong Rongjie Feng Xingyu Zhu Kang Xu Mingjie Kuang Wei Chong |
| author_facet | Hao Chen Yang Zhong Yang Zhong Rongjie Feng Xingyu Zhu Kang Xu Mingjie Kuang Wei Chong |
| author_sort | Hao Chen |
| collection | DOAJ |
| description | Recent studies reported that cytoplasmic dsDNA-induced activation of cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling has tremendous potential for antitumor immunity by inducing the production of type I Interferon (IFN), resulting in activation of both innate and adaptive immunity. However, the potential role of STING signaling in modulating immunological checkpoint inhibitor (CPI) therapeutic efficacy remains unexplored. In this research, we employed the single-sample gene set enrichment analysis (ssGSEA) algorithm to calculate the enrichment score of STING signaling across 15 immunotherapy cohorts, including melanoma, lung, stomach, urothelial, and renal cancer. Logistic and Cox regression models were utilized to investigate the association between STING signaling and checkpoint inhibitor therapeutic response. Furthermore, we evaluated the tumor immunogenicity of STING1 molecule expression in the Cancer Genome Atlas (TCGA) pan-cancer datasets. STING signaling was associated with improved immune response in the Mariathasan2018_PD-L1, Gide2019_combined, Jung2019_PD-1/L1, and Gide2019_PD-1 datasets and with prolonged overall survival in the Gide2019_PD-1, Nathanson2017_post, Jung2019_PD-1/L1, and Mariathasan2018_PD-L1 datasets. However, the Braun_2020_PD-1 cohort exhibited worse prognosis outcomes in the high STING signaling subgroup. Our study extended the molecular knowledge of STING signaling activation in regulating the antitumor immune response and provided clinical clues about the combination treatments of STING agonists and CPIs for improving tumor therapeutic efficacy. |
| format | Article |
| id | doaj-art-0ea7bedf65f8423897f121dd8e6bfd8d |
| institution | OA Journals |
| issn | 2296-889X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj-art-0ea7bedf65f8423897f121dd8e6bfd8d2025-08-20T01:51:54ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2025-05-011210.3389/fmolb.2025.15567361556736Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapyHao Chen0Yang Zhong1Yang Zhong2Rongjie Feng3Xingyu Zhu4Kang Xu5Mingjie Kuang6Wei Chong7Clinical Research Center of Shandong University, Clinical Epidemiology Unit, School of Public Health, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, ChinaClinical Research Center of Shandong University, Clinical Epidemiology Unit, School of Public Health, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, ChinaDepartment of Epidemiology and Health Statistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, ChinaDepartment of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Key Laboratory of Engineering of Shandong Province, Jinan, Shandong, ChinaDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Key Laboratory of Engineering of Shandong Province, Jinan, Shandong, ChinaDepartment of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Key Laboratory of Engineering of Shandong Province, Jinan, Shandong, ChinaRecent studies reported that cytoplasmic dsDNA-induced activation of cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling has tremendous potential for antitumor immunity by inducing the production of type I Interferon (IFN), resulting in activation of both innate and adaptive immunity. However, the potential role of STING signaling in modulating immunological checkpoint inhibitor (CPI) therapeutic efficacy remains unexplored. In this research, we employed the single-sample gene set enrichment analysis (ssGSEA) algorithm to calculate the enrichment score of STING signaling across 15 immunotherapy cohorts, including melanoma, lung, stomach, urothelial, and renal cancer. Logistic and Cox regression models were utilized to investigate the association between STING signaling and checkpoint inhibitor therapeutic response. Furthermore, we evaluated the tumor immunogenicity of STING1 molecule expression in the Cancer Genome Atlas (TCGA) pan-cancer datasets. STING signaling was associated with improved immune response in the Mariathasan2018_PD-L1, Gide2019_combined, Jung2019_PD-1/L1, and Gide2019_PD-1 datasets and with prolonged overall survival in the Gide2019_PD-1, Nathanson2017_post, Jung2019_PD-1/L1, and Mariathasan2018_PD-L1 datasets. However, the Braun_2020_PD-1 cohort exhibited worse prognosis outcomes in the high STING signaling subgroup. Our study extended the molecular knowledge of STING signaling activation in regulating the antitumor immune response and provided clinical clues about the combination treatments of STING agonists and CPIs for improving tumor therapeutic efficacy.https://www.frontiersin.org/articles/10.3389/fmolb.2025.1556736/fullcGAS/STINGcheckpoint inhibitors therapytumor immunogenomicspredictive markerCPI |
| spellingShingle | Hao Chen Yang Zhong Yang Zhong Rongjie Feng Xingyu Zhu Kang Xu Mingjie Kuang Wei Chong Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy Frontiers in Molecular Biosciences cGAS/STING checkpoint inhibitors therapy tumor immunogenomics predictive marker CPI |
| title | Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy |
| title_full | Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy |
| title_fullStr | Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy |
| title_full_unstemmed | Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy |
| title_short | Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy |
| title_sort | clinical and molecular implications of cgas sting signaling in checkpoint inhibitor immunotherapy |
| topic | cGAS/STING checkpoint inhibitors therapy tumor immunogenomics predictive marker CPI |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2025.1556736/full |
| work_keys_str_mv | AT haochen clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy AT yangzhong clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy AT yangzhong clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy AT rongjiefeng clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy AT xingyuzhu clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy AT kangxu clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy AT mingjiekuang clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy AT weichong clinicalandmolecularimplicationsofcgasstingsignalingincheckpointinhibitorimmunotherapy |